Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review

Journal of Clinical Oncology

Volumn 25, Issue 21, 2007, Pages 3158-3167

  Kuderer, Nicole M ^a   Dale, David C ^a   Crawford, Jeffrey ^a   Lyman, Gary H ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; MITOXANTRONE; PLACEBO; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ANTIBIOTIC THERAPY; BONE PAIN; CANCER PATIENT; CHEMOTHERAPY; CLINICAL TRIAL; CONFIDENCE INTERVAL; DATA BASE; DATA EXTRACTION; DERSIMONIAN METHOD; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; LAIRD METHOD; LYMPHOMA; MANTEL HAENSZEL TEST; META ANALYSIS; MORTALITY; MUSCULOSKELETAL PAIN; NEUTROPHIL COUNT; PARAMETER; PRIORITY JOURNAL; PROPHYLAXIS; RELATIVE DOSE INTENSITY; REVIEW; RISK FACTOR; RISK REDUCTION; SOLID TUMOR; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEVER; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; NEOPLASMS; NEUTROPENIA; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34547670214     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.8823     Document Type: Review

References (81)

1. Kuderer NM, Dale DC, Crawford J, et al: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258-2266, 2006
2. Talcott JA, Siegel RD, Finberg R, et al: Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 10:316-322, 1992
3. Klastersky J, Paesmans M, Rubenstein EB, et al: The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038-3051, 2000
4. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, et al: Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia. Eur J Clin Microbiol Infect Dis 18:539-544, 1999
5. Malik I, Hussain M, Yousuf H: Clinical characteristics and therapeutic outcome of patients with febrile neutropenia who present in shock: Need for better strategies. J Infect 42:120-125, 2001
6. Darmon M, Azoulay E, Alberti C, et al: Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients. Intensive Care Med 28:1775-1780, 2002
7. Elting LS, Rubenstein EB, Rolston KV, et al: Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25:247-259, 1997
8. Carratala J, Roson B, Fernandez-Sevilla A, et al: Bacteremic pneumonia in neutropenic patients with cancer: Causes, empirical antibiotic therapy, and outcome. Arch Intern Med 158:868-872, 1998
9. Rossini F: Prognosis of infections in elderly patients with haematological diseases. Support Care Cancer 4:46-50, 1996
10. Gabrilove JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988
11. Morstyn G, Campbell L, Lieschke G, et al: Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol 7:1554-1562, 1989
12. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991
13. Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319-324, 1993
14. Welte K, Gabrilove J, Bronchud MH, et al: Filgrastim (r-metHuG-CSF): the first 10 years. Blood 88:1907-1929, 1996
15. Pettengell R, Gurney H, Radford JA, et al: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430-1436, 1992
16. Chevallier B, Chollet P, Merrouche Y, et al: Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 13:1564-1571, 1995
17. Bui BN, Chevallier B, Chevreau C, et al: Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol 13:2629-2636, 1995
18. Zinzani PL, Pavone E, Storti S, et al: Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 89:3974-3979, 1997
19. Gisselbrecht C, Haioun C, Lepage E, et al: Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: Factors influencing chemotherapy administration - Groupe d'Etude des Lymphomes de l'Adulte. Leuk Lymphoma 25:289-300, 1997
20. Fossa SD, Kaye SB, Mead GM, et al: Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy: European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 16:716-724, 1998
21. Lyman GH, Kuderer NM, Djulbegovic B: Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: A meta-analysis. Am J Med 112:406-411, 2002
22. Dickersin K, Scherer R, Lefebvre C: Identifying relevant studies for systematic reviews. BMJ 309:1286-1291, 1994
23. Higgins JPT, Green S Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. Oxford, United Kingdom, The Cochrane Collaboration, 2005
24. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006
25. Crawford J, Althaus B, Armitage J, et al: Myeloid growth factors: Clinical practice guidelines in oncology. J Natl Compr Cane Netw 5:188-202, 2007
26. Crawford J, Althaus B, Armitage J, et al: Myeloid growth factors clinical practice guidelines in oncology. J Natl Compr Cane Netw 3:540-555, 2005
27. Hartmann LC, Tschetter LK, Habermann TM, et al: Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 336:1776-1780, 1997
28. Burton C, Linch D, Hoskin P, et al: A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma. Br J Cancer 94:806-813, 2006
29. Dunlop DJ, Eatock MM, Paul J, et al: Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease: West of Scotland Lymphoma Group. Clin Oncol (R Coll Radiol) 10:107-114, 1998
30. Bassan R, Lerede T, Di Bona E, et al: Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: Effects, role of patient pretreatment characteristics, and costs. Leuk Lymphoma 26:153-161, 1997
31. Crawford J, Kreisman H, Garewal H, et al: The impact of filgrastim schedule variation on hematopoietic recovery post-chemotherapy. Ann Oncol 8:1117-1124, 1997
32. Lokich JJ: Same day pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma. Am J Clin Oncol 29:361-363, 2006
33. Kaufman PA, Paroly W, Rinaldi D, et al: Randomized double-blind phase 2 study evaluating same-day vs next-day administration of pegfilgrastim with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with early stage and advanced breast cancer. Breast Cancer Res Treat 88:559, 2004 (abstr 1054)
34. Bohlius J, Reiser M, Schwarzer G, et al: Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: A systematic review. Br J Haematol 122:413-423, 2003
35. Moher D, Jadad AR, Nichol G, et al: Assessing the quality of randomized controlled trials: An annotated bibliography of scales and checklists. Control Clin Trials 16:62-73, 1995
36. Cochran WG: The combination of estimates from different experiments. Biometrics 10:101-129, 1954
37. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558, 2002
38. Higgins JP, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-analyses. BMJ 327:557-560, 2003
39. Fleiss JL: The statistical basis of meta-analysis. Stat Methods Med Res 2:121-145, 1993
40. Yusuf S, Wittes J, Probstfield J, et al: Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 266:93-98, 1991
41. Altman DG, Bland JM: Interaction revisited: The difference between two estimates. BMJ 326:219, 2003
42. Cohen J: Statistical Power Analysis for the Behavioral Sciences (ed 2). Hillsdale, NJ, Lawrence Earlbaum Associates, 1988
43. Gatzemeier U, Kleisbauer JP, Drings P, et al: Lenograstim as support for ACE chemotherapy of small-cell lung cancer: A phase III, multicenter, randomized study. Am J Clin Oncol 23:393-400, 2000
44. Gebbia V, Testa A, Valenza R, et al: A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma. J Chemother 5:186-190, 1993
45. Gebbia V, Valenza R, Testa A, et al: A prospective randomized trial of thymopentin versus granulocyte-colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy. Anticancer Res 14:731-734, 1994
46. Doorduijn JK, van der Holt B, van Imhoff GW, et al: CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 21:3041-3050, 2003
47. Osby E, Hagberg H, Kvaloy S, et al: CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: Results of a Nordic Lymphoma Group randomized trial. Blood 101:3840-3848, 2003
48. Timmer-Bonte JN, de Boo TM, Smit HJ, et al: Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: A Dutch randomized phase III study. J Clin Oncol 23:7974-7984, 2005
49. Muhonen T, Jantunen I, Pertovaara H, et al: Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer: A randomized study. Am J Clin Oncol 19:232-234, 1996
50. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al: First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178-1184, 2005
51. Clark OA, Lyman GH, Castro AA, et al: Colony-stimulating factors for chemotherapy-induced febrile neutropenia: A meta-analysis of randomized controlled trials. J Clin Oncol 23:4198-4214, 2005
52. Papaldo P, Lopez M, Marolla P, et al: Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 23:6908-6918, 2005
53. Fridrik MA, Greil R, Hausmaninger H, et al: Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL): A multicenter trial by the Austrian Working Group for Medical Tumor Therapy. Ann Hematol 75:135-140, 1997
54. Aglietta M, Montemurro F, Fagioli F, et al: Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease. Cancer 88:454-460, 2000
55. Lyman GH, Dale DC, Crawford J: Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J Clin Oncol 21:4524-4531, 2003
56. Lyman GH, Dale DC, Friedberg J, et al: Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: A nationwide study. J Clin Oncol 22:4302-4311, 2004
57. Dale DC, McCarter GC, Crawford J, et al: Myelotoxicity and dose intensity of chemotherapy: Reporting practices from randomized clinical trials. J Natl Compr Cane Netw 1:440-454, 2003
58. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
59. Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641, 2004
60. Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 104:626-633, 2004
61. Wunderlich A, Kloess M, Reiser M, et al: Practicability and acute haematological toxicity of 2-and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: Results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 14:881-893, 2003
62. Burstein HJ, Parker LM, Keshaviah A, et al: Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 23:8340-8347, 2005
63. Kummel S, Krocker J, Kohls A, et al: Randomised trial: Survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. Br J Cancer 94:1237-1244, 2006
64. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003
65. Woll PJ, Hodgetts J, Lomax L, et al: Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 13:652-659, 1995
66. Hidalgo M, Mendiola C, Lopez-Vega JM, et al: A multicenter randomized phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma: PSAMOMA Cooperative Group, Spain. Cancer 83:719-725, 1998
67. Fukuoka M, Masuda N, Negoro S, et al: CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 75:306-309, 1997
68. Sternberg CN, de Mulder PH, Schornagel JH, et al: Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19:2638-2646, 2001
69. American Society of Clinical Oncology: Recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 12:2471-2508, 1994
70. Aapro MS, Cameron DA, Pettengell R, et al: EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433-2453, 2006
71. Gerhartz HH, Engelhard M, Brittinger G, et al: Recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to chemotherapy in aggressive non-Hodgkin's lymphomas. Semin Oncol 21:25-28, 1994
72. Lyman GH, Kuderer NM: The strengths and limitations of meta-analyses based on aggregate data. BMC Med Res Methodol 5:14, 2005
73. Olkin I, Sampson A: Comparison of meta-analysis versus analysis of variance of individual patient data. Biometrics 54:317-322, 1998
74. Mathew T, Nordstrom K: On the equivalence of meta-analysis using literature and using individual patient data. Biometrics 55:1221-1223, 1999
75. Angelillo IF, Villari P: Meta-analysis of published studies or meta-analysis of individual data? Caesarean section in HIV-positive women as a study case. Public Health 117:323-328, 2003
76. Hassett MJ, O'Malley AJ, Pakes JR, et al: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1108-1117, 2006
77. Russo A, Autelitano M, Bisanti L: Re: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1826-1827, 2006
78. Timmer-Bonte JN, Adang EM, Smit HJ, et al: Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol 24:2991-2997, 2006
79. Lyman GH, Kuderer N, Greene J, et al: The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. Eur J Cancer 34:1857-1864, 1998
80. Calhoun EA, Schumock GT, McKoy JM, et al: Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer: The 40% rule revisited. Pharmacoeconomics 23:767-775, 2005
81. Cosier LE, Calhoun EA, Agboola O, et al: Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 24:488-494, 2004